UPDATE : Monday, December 17, 2018
상단여백
CrystalGenomics to change molecular targeted therapy from injection to oral drug in trials
CrystalGenomics said it would change the form of an investigational molecul...
by Nam Doo-hyun  |  2018-10-30 10:52
라인
‘I will help make Korea original holder of anticancer drugs’
“Original technologies are important for national development. We will deve...
by So Jae-hyeon  |  2018-10-29 14:43
라인
‘Bio Solution’s value to rise on arthritis cell therapy’
Bio Solution will be able to drive up its market capitalization once it obt...
by Nam Doo-hyun  |  2018-10-25 16:30
라인
Samsung BioLogics posts ₩101.1 billion in Q3 sales
Samsung BioLogics said Wednesday that it recorded 101.1 billion won ($88.7 ...
by Lee Han-soo  |  2018-10-25 11:02
라인
CancerRop advances into Malaysian gene market
CancerRop said Wednesday that it has signed a cooperative agreement with Ca...
by Lee Han-soo  |  2018-10-24 17:49
라인
Celltrion releases clinical trial results for Remsima SC in EU and US
Celltrion has presented phase 1 and 3 clinical trials for Remsima SC, the s...
by Lee Han-soo  |  2018-10-24 16:47
라인
Will synthetic biology be vital in smart therapeutics?
Synthetic biology, which designs biological components and systems in new w...
by Nam Doo-hyun  |  2018-10-24 16:40
라인
Biotech shares tank amid nosediving of Seoul stocks
Biotech and pharmaceutical shares plunged on Tuesday, hurt mainly by the ov...
by Nam Doo-hyun  |  2018-10-24 11:35
라인
‘Antibody drug developer AbClon noteworthy’
AbClon, a developer of innovative antibody medicines, is likely to achieve ...
by Nam Doo-hyun  |  2018-10-22 14:49
라인
L&C BIO sets offering price at ₩24,000 for KOSDAQ debut
L&C BIO, a tissue engineering company, said on Friday that it has set its o...
by So Jae-hyeon  |  2018-10-22 14:12
라인
'Superbug' fears bring antibiotics developers under spotlight
Investors are paying keen attention to antibiotics developers amid growing ...
by Nam Doo-hyun  |  2018-10-22 11:53
라인
Celltrion, Samsung BioLogics named Fortune’s ‘Future 50’
Fortune, a U.S.-based multinational business magazine, has named Samsung Bi...
by Lee Han-soo  |  2018-10-19 16:34
라인
CancerRop launches unit to develop cell therapies
CancerRop established CancerRop Cell on Wednesday, a subsidiary to develop ...
by Lee Han-soo  |  2018-10-18 15:25
라인
Biogen, Samsung Bioepis announce European launch of Imraldi
Biogen and Samsung Bioepis said Tuesday they will launch Imraldi, the compa...
by Lee Han-soo  |  2018-10-17 17:28
라인
Bio stocks listed under ‘tech exception policy’ perform better
Biotech and medical companies that went public under the Korea Exchange’s “...
by Nam Doo-hyun  |  2018-10-15 12:27
라인
Merck to supply Samsung’s biosimilar to US Veterans Affairs Dept.
Merck, known as MSD outside the United States and Canada, announced that is...
by Lee Han-soo  |  2018-10-11 16:31
라인
US drug advisory recommends Celltrion’s Rituxan biosimilar for approval
Celltrion said Thursday that the U.S. Oncologic Drug Advisory Committee (OD...
by Lee Han-soo  |  2018-10-11 12:10
라인
‘Korea publishes many biotech papers but rarely links them to biz’
South Korea’s ranking in biotech competitiveness, announced by the U.S. sci...
by Nam Doo-hyun  |  2018-10-10 16:35
라인
GC opens new cell research center
GC said Monday that it has dedicated a new integrated research center in a ...
by Lee Han-soo  |  2018-10-10 11:45
라인
More biotech stocks come in top 20 on KOSDAQ
The number of pharmaceutical and biotech firms within the top 20 companies ...
by Nam Doo-hyun  |  2018-10-10 11:20
여백
여백
여백
Back to Top